series-c-plus
Stage
1
Investors
About
Allogene develops allogeneic CAR T cell therapies for the treatment of blood cancers, solid tumors, and autoimmune diseases using gene-engineering and gene-editing technologies to create off-the-shelf cell therapy products.
Explore Allogene's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.